BenzingaAugust 13, 2026 at 7:07 AM NY22 days ago

RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66

RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story